Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Innovators: Naturalock Solutions

Get in Touch

Innovators: Naturalock Solutions
By Brian Brus
Copyright © 2015 The Journal Record

NORMAN – Naturalock Solutions LLC has issued its first patent for what company President Gary Rayburn called a solution to significantly reducing catheter infections and health complications.

Development of the transdermal venous access locking technology – an injectable liquid to replace commonly used chemicals such as heparin and saline – had stagnated under the licensing of another company for more than two years, Rayburn said. Now Naturalock will be able to move forward unhindered under its parent Organic Medical Ventures LLC.

Rayburn credited the efforts of intellectual property attorney Bryan Fuller at the Hall Estill law firm in Oklahoma City for a quick rebound from the previous business relationship and filing the patent with the U.S. Patent and Trademark Office. The patent will be instrumental in commercialization of the Karaphor solution, he said.

Catheters are effectively open wounds and the needle resting in pierced flesh provides a lot of opportunity for infection, Rayburn said.

Catheter-related bloodstream infections are one of the top health care challenges in the industry as identified by the federal Centers for Disease Control and Prevention. More than 400,000 cases are reported annually, resulting in mortality rates as high as 25 percent. On the level of cost analysis, catheter infections are estimated to increase treatment costs $25,000 to $55,000, according to CDC data.

Karaphor is made from naturally occurring substances that help prevent coagulation and improve antimicrobial activity in catheters. The solution was designed to be flushed into a patient, a different approach than using products such as saline and heparin that need to be withdrawn and do not provide any antimicrobial properties.

“Our product would be utilized as a preventative measure,” he said. “If you have the option of curing a disease or preventing it, the best solution is obviously to prevent it to begin with.”

With Fuller’s help in defining the product’s widespread implications, the patent will also make it easier for Naturalock to commercialize a platform for related applications such as military field use, he said.

Naturalock is seeking partners to help commercialize the product and its potential portfolio, Rayburn said. He thanked the Norman Economic Development Coalition for its support during the company’s growth.

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E